Regencell Corp - דינמיקת הכנסות משנה לשנה ב-12 החודשים האחרונים RGC

The risk of capital depletion due to failed autism and ADHD tests poses a threat to the capital of Regencell Bioscience (RGC). The GURU.Markets portal illustrates the year-over-year sales trend over a 12-month period, where 0.00 serves as the final level marker. The business relies on a closed-loop system of Chinese medicine, while extract patents and strict committee oversight protect developments from replication.

This metric reflects the annual revenue trend over twelve trailing months relative to the same period last year, neutralizing seasonality and infrequent reporting. For Regencell Bioscience (RGC), this metric is critical, as the absence of commercial barriers leaves the company vulnerable to competitors. By analyzing the YoY revenue growth trend for TTM, an investor can discern the actual speed of business scaling. This indicator allows for the identification of an expansion phase or stagnation before market capacity is exhausted.